Semalutide, a glucagon like peptide (GLP-1) receptor agonist, has been approved for the treatment of type 2 diabetes. Somaglutide was developed by Novo Nordisk in 2012 as a long-term alternative to Liraglutide. Compared with Liraglutide and other Diabetes medication, one of the advantages of Somaglutide is that it has a long action time, so once a week injection is enough. In December 2017, the US Food and Drug Administration (FDA) approved the injection type of somalutide. A previous phase II clinical trial found that Somaglutide reduced the weight of type 2 diabetes patients and obese people, and weight loss was considered to be due to the reduction of energy intake caused by the reduction of appetite.